PRI

PRIMERICA, INC. · NYSE

News

3 latest

Zacks Investment Research

5 Insurance Stocks That Are Set for Q3 Earnings Outperformance

Five insurance companies—RenaissanceRe, MetLife, Primerica, Ryan Specialty Holdings, and Unum Group—are expected to exceed third-quarter 2026 earnings estimates. The insurance sector is benefiting from prudent pricing, strong policy retention, a benign catastrophe environment, higher interest rates boosting investment income, and digital acceleration. However, pricing pressures and competitive challenges persist across the industry.

Zacks Investment Research

Will Primerica (PRI) Beat Estimates Again in Its Next Earnings Report?

Primerica (PRI), a life insurance and financial products company, has demonstrated a strong track record of beating earnings estimates with an average surprise of 8.45% over the last two quarters. The company has a positive Earnings ESP of +0.35% combined with a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on November 4, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time.

Mentions PRI

Zacks Investment Research

CNO Financial to Report Q3 Earnings: What Should We Expect?

CNO Financial is set to report Q3 2026 earnings on October 29 with projected EPS of $1.09 (up 13.5%) but revenues expected to fall 16.7% to $993M. While the company has beaten earnings estimates for four consecutive quarters, its 0.00% Earnings ESP suggests an uncertain outlook for the upcoming quarter. Growth in health, Medicare Supplement, annuity, and Worksite sales may be offset by weaker Consumer life sales and higher technology modernization expenses.

Headlines link to the publisher. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.